scholarly journals A Randomized, Prospective Study to Compare the Efficacy and Safety of Omega-3 Fatty Acids as Additional Therapy to Methotrexate versus Methotrexate Monotherapy in the Management of Moderate to Severe Plaque Psoriasis

2021 ◽  
Vol 6 (1) ◽  
pp. 1
Author(s):  
Ankita Bedwal ◽  
Kavitha Rajarathna ◽  
Revathi T.N.
Keyword(s):  
Fatty Acids ◽  
Adverse Events ◽  
Plaque Psoriasis ◽  
Epigastric Pain ◽  
Omega 3 Fatty Acids ◽  
Efficacy And Safety ◽  
Omega 3 ◽  
Severe Plaque Psoriasis ◽  
Number Of Patients ◽  
The Difference

Psoriasis is a chronic, inflammatory, hyperproliferative, immune-mediated skin disorder, having a prevalence of 0.44-2.8% in India. Methotrexate is a widely used systemic regimen for moderate to severe psoriasis. Supplementation of omega-3 fatty acids has decreased the severity of the disease in some studies. This study aimed to assess the efficacy and safety of omega-3 fatty acids as an add-on to methotrexate versus methotrexate monotherapy in patients with moderate to severe plaque psoriasis. A total of 40 patients with moderate to severe plaque psoriasis were recruited in the study and randomized into two groups of 20 patients each. Group O received omega-3 fatty acids as add-on to methotrexate and Group M received methotrexate monotherapy. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Physician’s Global Assessment (PGA) were assessed at baseline, 4 weeks, 8 weeks and 12 weeks of treatment. The adverse events were assessed throughout the study period. There was a significant decrease in PASI and DLQI scores from baseline to end of 12 weeks in both groups (p<0.001) but the difference between the two groups was not significant (p>0.05). A higher number of patients had a PGA score of 0 or 1 at the end of 12 weeks in Group O (60%) as compared to Group M (40%) but the difference between the groups was not significant (p=0.34). The treatment was well tolerated in both the groups, with most common adverse events being nausea, diarrhea and epigastric pain. This study showed that the treatment in both the groups was equally effective in decreasing the severity of psoriasis and was well tolerated.

scholarly journals Omega-3 Fatty Acid Oil Enhancement of a Protein-Based Recovery Beverage: Sensory Analysis with Athletes

2017 ◽  
Vol 6 (4) ◽  
pp. 83
Author(s):  
Jessica Marie MacMartin ◽  
W. E. Buckley ◽  
David Cranage ◽  
Tim Bream ◽  
Peter Lawrence Bordi
Keyword(s):  
Fatty Acids ◽  
Sensory Analysis ◽  
Female Athlete ◽  
Daily Intake ◽  
The United States ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
United States Population ◽  
The Difference

Essential omega-3 fatty acids must be consumed through the diet to meet the body’s nutrition requirement. Daily-recommended intake of omega-3 fatty acids for adults is 270 milligrams/day. These fatty acids are commonly consumed through fish, but it is known that the United States population at large is not meeting their recommended daily intake. Supplements containing these important acids should be considered to close the gap between recommendations and actual intake. To create a product with these beneficial acids, sensory analysis was conducted to see if non-trained male and female athlete panelists could notice the difference in several key sensory characteristics (appearance, initial taste, color, sweetness, consistency, chocolate flavor, aftertaste, overall quality and overall liking) in a chocolate protein-based recovery beverage. The sensory-neutral oil was added into the beverage and athletes (n=95) were asked to taste the omega-3 and original beverage and rank each characteristic on hedonic and just-about-right scales. Color of the drink, aftertaste, overall quality and overall liking were rated significantly higher for the omega-3 added drink. Overall, the addition of the omega-3 fatty acids improved the beverage in several key attributes and can be added into the final formulation of the product. 

scholarly journals Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation

JAMA ◽  
2010 ◽  
Vol 304 (21) ◽  
pp. 2363 ◽  
Author(s):  
Peter R. Kowey ◽  
James A. Reiffel ◽  
Kenneth A. Ellenbogen ◽  
Gerald V. Naccarelli ◽  
Craig M. Pratt
Keyword(s):  
Atrial Fibrillation ◽  
Fatty Acids ◽  
Omega 3 Fatty Acids ◽  
Efficacy And Safety ◽  
Omega 3

scholarly journals Implementing High Energy Liquid Nutrition, Omega-3 Fatty Acids and Nutritional Supplements for the Treatment of Anorexia Nervosa

2017 ◽  
Vol 1 (1) ◽  
pp. 1-12
Author(s):  
Christoph Baumann ◽  
Christian Willaschek ◽  
Tuende Kertess-Szlaninka ◽  
Lang Johanna ◽  
Reiner Buchhorn
Keyword(s):  
Fatty Acids ◽  
Anorexia Nervosa ◽  
Weight Gain ◽  
Nutritional Supplements ◽  
High Energy ◽  
Historical Control ◽  
Control Group ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Number Of Patients

Objective: To assess the effect of different treatment approaches on the course of anorexia nervosa (AN) over time. Methods: The subjects were 27 hospitalized AN patients. In our retrospective analysis we compared weight gain in two groups. While one group was treated with a standard oral refeeding protocol (historical control) through January 2013 (N=16), the second group (highly standardized refeeding protocol) received a high energy liquid nutrition and nutritional supplements including omega-3 fatty acids (N=11). Results: On admission, the two groups were comparable in terms of height, weight, age and heart rate. At the end of our monitoring time frame of 25 days, weight gain was 121.4% higher in the highly standardized refeeding protocol group than in the historical control group (66.5 ±52.4 vs 147.3 ±55.7 grams/day; t-Test p=0.004; CI95%: 29.3-132.2). A carbohydrate rich diet clearly improved weight gain if high energy liquid nutrition was replaced by the diet according the patient’s own wishes. About 45% of our patients stated they were vegetarians at admission. However, we could not identify a vegetarian diet as a statistically significant negative prognostic factor for weight gain. Conclusion: The highly standardized refeeding protocol seems to be helpful in malnourished AN patients to improve weight gain without enhancing the risk of a refeeding syndrome. However, further studies with greater number of patients are needed to confirm the effectiveness of our standardized treatment protocol.

scholarly journals Role of blood plasma fatty acids in pathogenesis of stable anginapectoris

2007 ◽  
Vol 6 (4) ◽  
pp. 41-45
Author(s):  
V. V. Novitsky ◽  
R. S. Karpov ◽  
S. V. Klimenkov ◽  
A. B. Salmina ◽  
M. Yu. Kotlovsky ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Fatty Acid ◽  
Saturated Fatty Acids ◽  
Control Group ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Men And Women ◽  
Number Of Patients ◽  
Omega 6 ◽  
Functional Classes

In men and women suffering from stable angina pectoris of 1-2 functional classes and aged from 35 to 69 years old, decrease of C 23:0 and increase of C 18:1(11) fatty acids was observed regardless of sex, the content of the rest fatty acids changed depending on patients sex. Correlation was found that metabolism of fatty acids in this pathology group depends on patients sex: men in the control group showed decrease in the sum of omega-3 fatty acids as well as in the omega-3/omega-6 fatty acid ratio, while women showed decrease of omega-6 fatty acids at the constant sum of omega-3 fatty acids. Regardless of sex, the presence of this pathology is accompanied with decrease in correlations between fatty acids, as the number of correlations between saturated fatty acids increases and the number of correlations between not saturated and saturated fatty aсids decreases. Change in correlations between not saturated fatty acids depends on sex. In the number of patients having supernormal fatty acid contents, no pronounced differences were found between men and women.

scholarly journals Efficacy and safety of parenteral omega 3 fatty acids in ventilated patients with acute lung injury

2011 ◽  
Vol 15 (2) ◽  
pp. 108-113 ◽  
Author(s):  
Sweta Patel ◽  
Ajay Gupta ◽  
Shaleen Bhatnagar ◽  
Jyoti Goyal ◽  
Himanshu Baweja
Keyword(s):  
Fatty Acids ◽  
Acute Lung Injury ◽  
Lung Injury ◽  
Omega 3 Fatty Acids ◽  
Efficacy And Safety ◽  
Omega 3 ◽  
Ventilated Patients

scholarly journals Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jing Yang ◽  
Zongming Wang ◽  
Xilin Zhang
Keyword(s):  
Adverse Events ◽  
Randomized Controlled Trials ◽  
Plaque Psoriasis ◽  
Sensitivity Analyses ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Severe Plaque Psoriasis ◽  
Randomized Controlled

Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Methods. A systematic review was undertaken to identify double-blind randomized controlled trials (RCTs). PubMed, Web of Science, Cochrane Library, EMBASE, and Google Scholar databases were searched before 1 March 2020. The odds ratios (ORs) with 95% confidence interval (CI) were calculated. All analyses were conducted with intention-to-treat basis. A range of sensitivity analyses was undertaken. Results. A total of 7 articles contained 1206 plaque psoriasis patients with guselkumab, 585 patients with placebo, and 1250 patients with adalimumab were included. The results indicated that guselkumab had better efficacy than placebo or adalimumab for Psoriasis Area and Severity Index score reductions from baseline of 75% (PASI 75) (OR=61.37, 95% CI=31.15 to 120.91; OR=3.08, 95% CI=2.35 to 4.06), Investigator’s Global Assessment scores of 0 or 1 (IGA 0/1) (OR=65.75, 95% CI=45.54 to 94.95; OR=2.79, 95% CI=2.17 to 3.59), and Dermatology Life Quality Index scores of 0 or 1 (DLQI 0/1) (OR=29.64, 95% CI=18.80 to 46.73; OR=1.86, 95% CI=1.50 to 2.31). The guselkumab had similar safety with placebo or adalimumab about the incidence of adverse events (AEs) (OR=1.05, 95% CI=0.86 to 1.29; OR=0.97, 95% CI=0.79 to 1.19) and serious adverse events (SAEs) (OR=1.03, 95% CI=0.47 to 2.27; OR=0.91, 95% CI=0.44 to 1.87). Meanwhile, there was no statistically significant association of infections and serious infections compared with the placebo or adalimumab group. The guselkumab was more effective and had the similar tolerance. Conclusion. The guselkumab had excellent efficacy and great safety in moderate-to-severe plaque psoriasis, but long-term safety remained to be determined.

Sign in / Sign up

Export Citation Format

Share Document